Skip to content

ENSYSCE BIOSCIENCES, INC.: 10-Q filed 2020-11-09

What ENSYSCE BIOSCIENCES, INC. reported in its quarterly report filed 2020-11-09 (fiscal Q3 2020): 21 published measures, 63 facts as tagged in accession 0001213900-20-035884.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-09
Fiscal period
fiscal Q3 2020
Accession
0001213900-20-035884 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENSYSCE BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3013,289,375USD
At 2019-12-31196,511,899USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-308,018,370USD
At 2019-12-3110,337,313USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-305,000,006USD
At 2020-06-305,000,003USD
At 2020-03-315,000,004USD
At 2019-12-315,000,001USD
At 2019-09-305,000,001USD
At 2019-06-305,000,001USD
At 2019-03-315,000,001USD
At 2018-12-315,000,001USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30218,823USD92
2020-01-01 to 2020-09-302,479,203USD274
2020-04-01 to 2020-06-302,610,234USD91
2020-01-01 to 2020-03-31-349,854USD91
2019-07-01 to 2019-09-30489,723USD92
2019-01-01 to 2019-09-301,684,538USD273
2019-04-01 to 2019-06-30418,902USD91
2019-01-01 to 2019-03-31775,913USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-468,847USD274
2019-01-01 to 2019-09-30-999,036USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-183,382,784USD274
2019-01-01 to 2019-09-30-8,640USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30182,843,972USD274
2019-01-01 to 2019-09-30623,204USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-304,935,997USD
At 2019-12-312,456,794USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-504,237USD92
2020-01-01 to 2020-09-30264,248USD274
2019-07-01 to 2019-09-3014,318USD92
2019-01-01 to 2019-09-30455,888USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-287,254USD92
2020-01-01 to 2020-09-30-1,274,109USD274
2019-07-01 to 2019-09-30-584,418USD92
2019-01-01 to 2019-09-30-1,399,530USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-30101,817USD
At 2019-12-311,199,722USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-30452,102USD
At 2019-12-312,771,045USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-30326,425USD
At 2019-12-312,771,045USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2020-03-01 to 2020-03-31136,283,492USD31

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-30287,254USD92
2020-01-01 to 2020-09-301,274,109USD274
2019-07-01 to 2019-09-30584,418USD92
2019-01-01 to 2019-09-301,399,530USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-306,257,127shares
At 2019-12-316,375,178shares

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-285,414USD92
2020-01-01 to 2020-09-302,743,451USD274
2019-07-01 to 2019-09-30504,041USD92
2019-01-01 to 2019-09-302,140,426USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-07-01 to 2020-09-30218,823USD92
2020-01-01 to 2020-09-302,479,203USD274
2019-07-01 to 2019-09-30489,723USD92
2019-01-01 to 2019-09-301,684,538USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30209,175USD92
2020-01-01 to 2020-09-302,471,558USD274
2019-07-01 to 2019-09-30-476,042USD92
2019-01-01 to 2019-09-30-1,082,288USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2019-01-01 to 2019-09-307,156USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-184,382,784USD274

Inspect the source

Entity
ENSYSCE BIOSCIENCES, INC. / CIK 0001716947
Captured
2026-09-21T17:24:39.335Z
SEC response SHA-256
28573a09f81da1511239531464c03b2552a3554a684a233653f365b194b6ca0b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001716947.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))